Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue from product sales	$ 215	$ 49	$ 300	$ 217
Collaboration revenue	0	30	18	193
Total revenue	215	79	318	410
Cost of product sales	287	62	696	283
Cost of collaboration revenue	0	142	1	230
Total cost of revenue	287	204	697	513
Gross loss	(72)	(125)	(379)	(103)
Research and development expense	1,645	2,394	6,599	7,208
Selling, general and administrative expense	2,723	2,477	8,003	9,041
Intangible asset impairment expense	0	0	3,905	0
Restructuring costs	43	0	335	0
Operating loss	(5,017)	(6,823)	(22,004)	(21,046)
Other income (expense):
Warrant revaluation income	3,007	5,301	10,518	4,240
Derivative revaluation expense	(251)	0	(251)	0
Interest expense	(46)	0	(46)	0
Other income (expense), net	8	1	(15)	4
Loss before income taxes	(2,299)	(1,521)	(11,798)	(16,802)
Income tax benefit	0	0	0	0
Net loss	$ (2,299)	$ (1,521)	$ (11,798)	$ (16,802)
Per Share Information:
Basic net loss (usd per share)	$ (0.05)	$ (0.04)	$ (0.27)	$ (0.40)
Diluted net loss (usd per share)	$ (0.05)	$ (0.07)	$ (0.31)	$ (0.44)
Weighted average number of common shares outstanding:
Basic weighted average number of common shares outstanding, shares	43,898,785	43,021,121	43,898,785	41,598,632
Diluted weighted average number of common shares outstanding, shares	43,898,785	43,712,918	43,922,808	41,829,231
Affiliated Entity
Research and development expense	$ 534	$ 1,827	$ 2,783	$ 4,694